Frost & Sullivan's industry research concludes, 'Masimo pulse oximetry is the
only vital sign module clinicians ask for by brand'
IRVINE, Calif., Nov. 20 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI),
the inventor of Pulse CO-Oximetry and Read-Through Motion and Low Perfusion
pulse oximetry, announced it has received a Frost & Sullivan 2007 Industry
Best Practices Award, for Pulse Oximetry Leadership -- "ranking number one
in the pulse oximetry industry." Frost & Sullivan further recognized "the
impressive progression of Signal Extraction Technology (Masimo SET) to the
'gold standard' for reliable pulse oximetry monitoring" in honoring the
company.
Superior Technology
Historically, the performance of conventional pulse oximetry, as well as
its usefulness in a variety of clinical settings, has been plagued by
interfering noise due to patient motion and low peripheral perfusion, which
often results in false SpO2 readings and frequent alarms. "Masimo Signal
Extraction Technology (SET) eliminates the issues caused by motion artifact
and low peripheral perfusion through proprietary signal processing algorithms
and sensor technologies," said Frost & Sullivan analyst Mike Arani in his
report.
Clinical Preference
Leading clinicians around the world have put the efficacy and reliability
of Masimo SET to the test in more than 100 independent and objective
peer-reviewed studies that prove Masimo's revolutionary Signal Extraction
Technology outperforms all others, even under the most demanding of clinical
conditions. "These clinical trials have not only proved the performance
superiority of Masimo SET, but time after time, they have also left a lasting
impression on the participating clinicians," the report said.
Brand Recognition
Also, according to the Frost & Sullivan report, "Masimo's strong brand
recognition has even driven major patient monitoring companies with in-house
proprietary SpO2 technologies to offer their multiparameter monitors with the
choice of Masimo SET SpO2 module." Today, Masimo SET technology is widely
integrated into more than 100 multiparameter monitors and over 40 monitoring
brands. "After all, performance superiority is the chief reason Masimo pulse
oximetry is the only vital sign module clinicians ask for by brand when
purchasing a patient-monitoring product," they added.
Market Achievements
Masimo's rapid market acceptance and market share gains were cited by
Frost & Sullivan as visible examples of this combination of superior
technology, clinical preference, brand recognition and exceptional brand
development success.
In selecting Masimo for the 2007 pulse oximetry brand development strategy
leadership award, Frost & Sullivan's analyst team tracked all the major
participants in the pulse oximetry industry. The process included in-depth
interviews with all market participants, customers and suppliers, along with
extensive secondary and technology research to identify best practices within
the industry. To determine the final ranking of competitors, Frost & Sullivan
measured each on the basis of: development of unique brand strategies,
competitor recognition and brand value, participation in industry trade
groups, establishment of programs that allow the brand's customers to grow,
and increases in customer loyalty. As a result of this ranking, Masimo topped
the list of industry competitors.
According to Frost & Sullivan manager Antonio Garcia, "The key to Masimo's
strong image lies in its vision of giving caregivers more options and
capabilities than they expect. After all, Masimo simply takes the guess work
out of pulse oximetry, so clinicians never have to guess what brand is the
most reliable."
Joe E. Kiani, Chairman and CEO of Masimo, said, "We are honored to receive
this award from Frost & Sullivan. This recognition is especially meaningful
because Frost & Sullivan has surveyed the market and responded with research
findings that validate what we have heard clinicians saying all along and what
our increasing marketshare momentum is a testament to-that clinicians
recognize Masimo SET is the best pulse oximetry technology for their
patients."
About Frost & Sullivan
Frost & Sullivan, a global growth consulting company, has been partnering
with clients to support the development of innovative strategies for more than
40 years. The company's industry expertise integrates growth consulting,
growth partnership services, and corporate management training to identify and
develop opportunities. Frost & Sullivan serves an extensive clientele that
includes Global 1000 companies, emerging companies and the investment
community by providing comprehensive industry coverage that reflects a unique
global perspective and combines ongoing analysis of markets, technologies,
econometrics, and demographics. For more information, visit
http://www.frost.com.
About Masimo
Masimo (Nasdaq: MASI) develops innovative monitoring technologies that
significantly improve patient care -- helping solve "unsolvable" problems. In
1995, the company debuted Read-Through Motion and Low Perfusion pulse
oximetry, known as Masimo SET, and with it virtually eliminated false alarms
and increased pulse oximetry's ability to detect life-threatening events. More
than 100 independent and objective studies have confirmed that Masimo SET
technology allows clinicians to accurately monitor blood oxygen saturation in
critical care situations. Our Masimo SET platform has significantly addressed
many of the previous technology limitations, has substantially contributed to
improved patient outcomes and has been referred to by several industry sources
as the gold standard in pulse oximetry. In 2005, Masimo introduced Masimo
Rainbow SET Pulse CO-Oximetry, which, for the first time, noninvasively
monitors the level of carbon monoxide and methemoglobin in the blood, allowing
early detection and treatment of potentially life-threatening conditions.
Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and
Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and
Applications." Additional information about Masimo and its products may be
found at http://www.masimo.com.
Contact:
Tom McCall
Masimo Corporation
949-297-7075
Masimo, SET, Signal Extraction Technology, Radical, Radical-7, Rad-57,
APOD, Improving Outcomes and Reducing Cost of Care by Taking Noninvasive
Monitoring to New Sites and Applications, Rainbow, SpCO, SpMet, and Pulse
CO-Oximeter are trademarks or registered trademarks of Masimo Corporation.
SOURCE Masimo Corporation